Clinical data, blood glucose, insulin, C-peptide, blood biochemistry, and other indicators were collected before and after treatment, and CMI was calculated.<h4>Results</h4>Short-term CSII treatment significantly improved blood glucose levels, insulin resistance, and pancreatic β-cell function in T2DM patients, while downregulating the CMI index (p = 0.002). The gene discussed is INS; the disease is type 2 diabetes mellitus.